Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2016-09-15 Director's Dealing
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is identified by the RNS Number header and contains a formal announcement dated September 15, 2016, regarding shareholding changes for Directors (Ian Page and Tony Griffin) under the Long Term Incentive Plan. The core content involves the 'Grant of nil cost options' and 'Grant of a conditional award' to directors, followed by detailed 'Notification of Dealing Forms' as required by the EU Market Abuse Regulation. This directly corresponds to the definition of Director's Dealing (insider trades/transactions by management). Therefore, the appropriate code is DIRS.
2016-09-15 English
Block listing Interim Review
Regulatory Filings Classification · 99% confidence The document is explicitly labeled with an "RNS Number" and contains the heading "BLOCK LISTING SIX MONTHLY RETURN". It details the status of unallotted securities under various share schemes (Long-Term Incentive Scheme, Approved Share Option Scheme, etc.) over a six-month period (March 15, 2016, to September 14, 2016). This type of periodic filing related to share capital movements and regulatory reporting, distributed via the RNS system, fits best under the general 'Regulatory Filings' category, as there is no specific code for a 'Block Listing Six Monthly Return'. While it relates to share capital, it is a regulatory compliance report rather than a direct announcement of a transaction (POS) or a general share issue (SHA). Given the RNS distribution and the nature of the required periodic disclosure, RNS is the most appropriate fallback.
2016-09-15 English
Approval for first US generic entrant antibiotic
Regulatory Filings Classification · 98% confidence The document is very short (2876 characters) and announces a specific piece of corporate news: FDA approval for a generic antibiotic. It is disseminated via 'RNS Number' and explicitly states, 'This information is provided by RNS The company news service from the London Stock Exchange' and that the information constitutes 'inside information' upon publication via the Regulatory Information Service. This structure strongly indicates a general regulatory announcement that does not fit the specific categories like ER (Earnings Release) or CAP (Financing Update). Therefore, the most appropriate classification is the general regulatory filing fallback category, RNS.
2016-09-09 English
Availability of 2016 Annual Report and Accounts
Report Publication Announcement Classification · 100% confidence The document is an announcement dated September 6, 2016, titled 'Availability of 2016 Annual Report and Accounts' from Dechra Pharmaceuticals PLC. It explicitly states that the '2016 Annual Report and Accounts is now available to view' and lists documents scheduled to be mailed, including the '2016 Annual Report and Accounts' and the 'Notice of the 2016 Annual General Meeting'. The text then proceeds to extract and present Key Performance Indicators (KPIs) and detailed sections on 'How the Business Manages Risk' and 'Internal Control Framework', which are typical components of a full Annual Report (10-K or equivalent). However, the primary purpose of this specific filing, given its structure and introductory nature announcing the availability of the full report, aligns best with a Report Publication Announcement (RPA) or a Regulatory Filing (RNS) if it were purely a notification. Since the document contains substantial extracted content from the Annual Report (KPIs, Risk Management, Controls) and is clearly announcing the release of the full annual filing, it is a notification about the annual report release. Given the options, 'RPA' (Report Publication Announcement) fits best as it announces the publication of the Annual Report and Accounts, even though it includes extracted data. If the full 10-K text were present, it would be 10-K. Since it's an announcement *about* the 10-K and AGM materials, RPA is the most precise fit for the announcement itself, adhering to Rule 2 (Menu vs Meal). The RNS number confirms it is a regulatory announcement.
2016-09-06 English
2016 Preliminary Results Announcement
Earnings Release Classification · 100% confidence The document is titled 'Preliminary Results Announcement' and contains detailed financial tables summarizing performance for the 'year ended 30 June 2016', including revenue, profit, and EPS figures. It explicitly states that the results are 'audited preliminary results'. This structure—a comprehensive summary of annual financial performance released shortly after the fiscal year-end, often accompanied by a briefing—strongly indicates an Annual Report or a document closely preceding it. However, the key differentiator here is the context: it is released via RNS (RNS Number : 8859I) and is explicitly called a 'Preliminary Results Announcement'. While a 10-K is the official, audited annual report filed with the SEC, this document serves as the primary, comprehensive financial disclosure for the year for a non-US entity (Dechra Pharmaceuticals PLC, likely UK-based given the London briefing address and RNS format) before the final 10-K equivalent filing. In the context of the provided definitions, a comprehensive report covering full financial performance for the year aligns best with the 'Annual Report (10-K)' definition, even if it is technically a 'Preliminary' announcement preceding the final filing. Given the depth of financial data (tables spanning multiple years and segments) and the focus on the full fiscal year, it is more substantial than an Earnings Release (ER) or Interim Report (IR). Since it covers the full year's performance, 10-K is the most appropriate classification among the choices for a comprehensive annual financial document. FY 2016
2016-09-05 English
Directorate Change
Board/Management Information Classification · 98% confidence The document is explicitly marked with an 'RNS Number' and contains the header 'Dechra Pharmaceuticals PLC' followed by an announcement dated 17 August 2016. The content details the 'Appointment of Chief Financial Officer' (Richard Cotton). This type of announcement regarding changes in senior management (Board Changes) is a standard regulatory disclosure. Based on the provided definitions, 'Board/Management Information' (MANG) is the most appropriate classification for an announcement detailing the appointment of a CFO. Although it carries an RNS number, the specific content points directly to MANG rather than the general 'RNS' fallback.
2016-08-17 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.